Jianming Xu

26.8k total citations · 7 hit papers
218 papers, 6.6k citations indexed

About

Jianming Xu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Jianming Xu has authored 218 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 142 papers in Oncology, 91 papers in Pulmonary and Respiratory Medicine and 56 papers in Surgery. Recurrent topics in Jianming Xu's work include Gastric Cancer Management and Outcomes (60 papers), Colorectal Cancer Treatments and Studies (55 papers) and Cancer Immunotherapy and Biomarkers (38 papers). Jianming Xu is often cited by papers focused on Gastric Cancer Management and Outcomes (60 papers), Colorectal Cancer Treatments and Studies (55 papers) and Cancer Immunotherapy and Biomarkers (38 papers). Jianming Xu collaborates with scholars based in China, United States and Japan. Jianming Xu's co-authors include Shukui Qin, Yuxian Bai, Rui‐Hua Xu, Yoon‐Koo Kang, Hyun Cheol Chung, Eric Van Cutsem, Hongming Pan, Shukui Qin, Ying Cheng and Atsushi Ohtsu and has published in prestigious journals such as Nature, The Lancet and Nature Communications.

In The Last Decade

Jianming Xu

202 papers receiving 6.5k citations

Hit Papers

Sunitinib Versus Sorafeni... 2013 2026 2017 2021 2013 2015 2014 2021 2013 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
    2013 586 citations Yoon‐Koo Kang, Shukui Qin et al. Journal of Clinical Oncology profile →
  2. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
    2015 553 citations Jin Li, Shukui Qin et al. profile →
  3. Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
    2014 474 citations Taroh Satoh, Rui‐Hua Xu et al. Journal of Clinical Oncology profile →
  4. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
    2021 449 citations Yuxian Bai, Jianming Xu et al. profile →
  5. Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial
    2013 417 citations Shukui Qin, Jianming Xu et al. Journal of Clinical Oncology profile →
  6. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
    2023 342 citations Yung‐Jue Bang, Manish A. Shah et al. profile →
  7. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
    2023 213 citations Yuxian Bai, Jianming Xu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jianming Xu China 33 3.8k 3.0k 1.5k 1.1k 1.1k 218 6.6k
Jonathan D. Schwartz United States 25 2.0k 0.5× 1.9k 0.6× 1.1k 0.7× 1.1k 1.0× 1.6k 1.4× 60 4.7k
Robert R. McWilliams United States 46 5.9k 1.5× 1.9k 0.6× 1.9k 1.2× 2.4k 2.1× 742 0.7× 206 8.4k
Allen Lee Cohn United States 38 4.7k 1.2× 2.4k 0.8× 875 0.6× 1.5k 1.4× 1.2k 1.1× 159 6.9k
Vincenzo Catalano Italy 40 3.1k 0.8× 1.6k 0.5× 1.2k 0.8× 1.4k 1.2× 667 0.6× 124 5.1k
Rosine Guimbaud France 34 7.7k 2.0× 2.5k 0.8× 2.3k 1.5× 1.5k 1.4× 899 0.8× 178 9.5k
Baki Topal Belgium 40 2.5k 0.6× 2.0k 0.7× 2.3k 1.5× 1.4k 1.3× 843 0.8× 100 5.6k
Mario Scartozzi Italy 44 3.7k 1.0× 2.1k 0.7× 834 0.6× 1.7k 1.5× 953 0.9× 343 6.4k
Manfred P. Lutz Germany 32 3.0k 0.8× 1.7k 0.6× 1.5k 1.0× 823 0.7× 834 0.7× 114 4.7k
Ferdinando De Vita Italy 43 3.4k 0.9× 2.2k 0.7× 1.2k 0.8× 2.0k 1.7× 266 0.2× 207 6.0k
Jianping Xiong China 36 2.0k 0.5× 1.6k 0.6× 772 0.5× 2.1k 1.8× 491 0.4× 189 5.0k

Countries citing papers authored by Jianming Xu

Since Specialization
Citations

This map shows the geographic impact of Jianming Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jianming Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jianming Xu more than expected).

Fields of papers citing papers by Jianming Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jianming Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jianming Xu. The network helps show where Jianming Xu may publish in the future.

Co-authorship network of co-authors of Jianming Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Jianming Xu. A scholar is included among the top collaborators of Jianming Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jianming Xu. Jianming Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
4.
Ni, Wenqing, Xueli Yuan, Yan Zhang, et al.. (2024). Association of hemoglobin levels with cause-specific and all-cause mortality among older adults: a prospective cohort study. Frontiers in Public Health. 12. 1435283–1435283. 1 indexed citations
5.
6.
Liang, Jiajian, Jianming Xu, Kewen Zhou, et al.. (2024). Oxidized low-density lipoprotein changes the inflammatory status and metabolomics profiles in human and mouse macrophages and microglia. Heliyon. 10(7). e28806–e28806. 1 indexed citations
7.
Xu, Jianming, Jianping Xiong, Shanzhi Gu, et al.. (2023). A phase 2 study of HMPL-453, a selective FGFR tyrosine kinase inhibitor (TKI), in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions.. Journal of Clinical Oncology. 41(16_suppl). e16118–e16118. 1 indexed citations
8.
Xu, Jianming, Jiuwei Cui, Haiping Jiang, Yan Zeng, & Xiuyu Julie Cong. (2023). Phase 1 dose escalation study of FGFR4 inhibitor in combination with pembrolizumab in advanced solid tumors patients. Cancer Medicine. 12(7). 7762–7771. 2 indexed citations
9.
Lin, Yan, Zhuoran Zhang, Wenli Yang, et al.. (2023). The FGFR1 Signaling Pathway Upregulates the Oncogenic Transcription Factor FOXQ1 to Promote Breast Cancer Cell Growth. International Journal of Biological Sciences. 19(3). 744–759. 12 indexed citations
10.
Qin, Shukui, Tianshu Liu, Jianming Xu, et al.. (2023). Impact of primary tumor side on clinical outcomes of first-line cetuximab plus FOLFOX-4 in RAS wild-type metastatic colorectal cancer. Future Oncology. 19(15). 1053–1061. 4 indexed citations
11.
Qin, Shukui, Jiafu Ji, Rui‐Hua Xu, et al.. (2021). Treatment Patterns and Outcomes in Chinese Patients with Gastric Cancer by HER2 Status: A Noninterventional Registry Study (EVIDENCE). The Oncologist. 26(9). e1567–e1580. 23 indexed citations
12.
Zhu, Wenjia, Ru Jia, Qiao Yang, et al.. (2021). A prospective randomized, double-blind study to evaluate the diagnostic efficacy of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with 68Ga-DOTATATE. European Journal of Nuclear Medicine and Molecular Imaging. 49(5). 1613–1622. 25 indexed citations
13.
Xu, Jianming, Yuxian Bai, Nong Xu, et al.. (2020). Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma. Clinical Cancer Research. 26(17). 4542–4550. 70 indexed citations
14.
Sun, Bin, Dong Yang, Hongjiu Dai, et al.. (2019). Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells. Cancer Immunology Research. 7(11). 1813–1823. 115 indexed citations
15.
Li, Zongcheng, Yuling Chen, Wu Ren, et al.. (2019). Transcriptome Alterations in Liver Metastases of Colorectal Cancer After Acquired Resistance to Cetuximab. Cancer Genomics & Proteomics. 16(3). 207–219. 9 indexed citations
16.
Xu, Rui‐Hua, Jin Li, Yuxian Bai, et al.. (2017). Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. Journal of Hematology & Oncology. 10(1). 63 indexed citations
17.
Satoh, Taroh, Rui‐Hua Xu, Hyun Cheol Chung, et al.. (2014). Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study. Journal of Clinical Oncology. 32(19). 2039–2049. 474 indexed citations breakdown →
18.
Cutsem, Eric Van, Sanne de Haas, Yoon‐Koo Kang, et al.. (2012). Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial. Journal of Clinical Oncology. 30(17). 2119–2127. 358 indexed citations
19.
Jia, Changku, Yuanbiao Zhang, Jianming Xu, & Ke Sun. (2012). Experience in primary hepatic neuroendocrine tumor. The Turkish Journal of Gastroenterology. 23(5). 546–551. 22 indexed citations
20.
Xu, Jianming, et al.. (1999). Predictive chemotherapy of advanced breast cancer directed by MTT assay in vitro. Breast Cancer Research and Treatment. 53(1). 77–85. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jonathan D. Schwartz Breakdown of academic impact, for papers by Robert R. McWilliams Breakdown of academic impact, for papers by Allen Lee Cohn Breakdown of academic impact, for papers by Vincenzo Catalano Breakdown of academic impact, for papers by Rosine Guimbaud Breakdown of academic impact, for papers by Baki Topal Breakdown of academic impact, for papers by Mario Scartozzi Breakdown of academic impact, for papers by Manfred P. Lutz Breakdown of academic impact, for papers by Ferdinando De Vita Breakdown of academic impact, for papers by Jianping Xiong
Rankless by CCL
2026